Clinical trials: Epidermolysis Bullosa
Epidermolysis Bullosa Simplex
Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita
This study evaluates the clinical effect of foot injection of the bacteria protein Botulinum toxin A on plantar pain in patients with EBS (epidermolysis bullosa simplex) or PC (pachyonychia congenita).
- Trial name
- NCT00936533
- Testing
- Dysport® (Botulinumtoxin A (Btx A))
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Uppsala University
Epidermolysis Bullosa
Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin
Dowling Meara type of epidermolysis bullosa simplex (EBS-DM) is a rare genodermatosis due to keratin 5 and 14 mutation, characterized by skin fragility and spontaneous or post traumatic blisters.
- Trial name
- NCT01340235
- Testing
- Oral erythromycin
- Where
- 4 sites in France
- Volunteers
- 8 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
RDEB, Recessive Dystrophic Epidermolysis Bullosa
GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment
This study is being done to find out if a new type of skin graft, called GMEB-SASS, is safe and effective for helping wounds heal in people with RDEB (Recessive Dystrophic Epidermolysis Bullosa).
- Conditions
- RDEB, Recessive Dystrophic Epidermolysis Bullosa, Epidermolysis Bullosa Dystrophica, Recessive
- Trial name
- NCT07193134
- Testing
- Genetically Modified Epidermolysis Bullosa Self-Assembled Skin Substitute (GMEB-SASS)
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- CHU de Quebec-Universite Laval
Recessive Dystrophic Epidermolysis Bullosa
Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa
The aim of this clinical trial is to investigate the efficacy (by monitoring overall improvement of EB symptoms) and safety (by monitoring adverse events) of three doses of allo-APZ2-EB administered intravenously to patients with…
- Trial name
- NCT03529877
- Testing
- allo-APZ2-EB
- Where
- 6 sites in United States, Austria and 3 more
- Volunteers
- 16 people
- Sponsor
- RHEACELL GmbH & Co. KG
Dystrophic Epidermolysis Bullosa
Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa
This is a phase I/II open-label study to evaluate the efficacy and safety of ALLO-ASC-DFU in patients with Dystrophic Epidermolysis Bullosa.
- Trial name
- NCT02579369
- Testing
- Allogeneic mesenchymal stem cells, Polyurethene Film
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Anterogen Co., Ltd.
Dystrophic Epidermolysis Bullosa
Evaluation of D-Fi for the Treatment of Wounds Due to DEB
The purpose of this study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic…
- Trial name
- NCT06892639
- Testing
- D-Fi
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Castle Creek Biosciences, LLC.
Recessive Dystrophic Epidermolysis Bullosa
A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting
The goal of this observational study is to evaluate the long-term safety and wound healing durability (up to 15 years) for participants with Recessive Dystrophic Epidermolysis Bullosa (RDEB) who were treated with pz-cel.
- Trial name
- NCT07700966
- Testing
- Prademagene Zamikeracel
- Where
- 4 sites in United States
- Volunteers
- 250 people
- Sponsor
- Abeona Therapeutics, Inc
Junctional Epidermolysis Bullosa
Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With JEB (HOLOGENE17)
Prospective open-label, uncontrolled clinical study to assess the safety and efficacy of autologous cultured epidermal grafts containing epidermal stem cells genetically modified with the aid of a gamma-retroviral vector carrying…
- Trial name
- HOLOGENE17 (NCT03490331)
- Testing
- Transplantation surgery of genetically corrected cultured epidermal autograft (ATMP)
- Where
- Austria
- Volunteers
- 1 people
- Sponsor
- Holostem s.r.l.
Epidermolysis Bullosa
A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
The purpose of this study is to investigate a treatment to enhance the healing of acute and chronic nonhealing cutaneous wounds, such as the erosions experienced by patients with Epidermolysis Bullosa (EB), by the known activity…
- Trial name
- NCT00311766
- Testing
- Thymosin Beta 4
- Volunteers
- 30 people
- Sponsor
- RegeneRx Biopharmaceuticals, Inc.
Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa
Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care
The purpose of this study is to test the effectiveness of Helicoll (a collagen wound dressing) in treating chronic and non-chronic wounds of recessive dystrophic epidermolysis bullosa (RDEB) patients.
- Trial name
- NCT01716169
- Testing
- Helicoll, Standard of Care Dressings
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Dystrophic Epidermolysis Bullosa
Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa
The objective of this study is to characterize the extent and severity of disease in subjects with DEB and the progression of disease over a timeframe relevant to interventional studies.
- Trial name
- NCT01768026
- Where
- United States
- Sponsor
- Lotus Tissue Repair, Inc.
Skin Diseases
Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders
Severe itch is a common symptom of many genetic skin disorders and leads to a negative impact on patient quality of life. The investigators hypothesize that: a) intervention with dupilumab will improve itch in patients with…
- Trial name
- NCT05649098
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
Dystrophic Epidermolysis Bullosa
Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene
A double-blind, randomized, intra-patient placebo- controlled, multiple dose study of PTW-002 evaluating safety, proof of mechanism, preliminary efficacy, and systemic exposure in patients with Dominant Dystrophic Epidermolysis…
- Trial name
- NCT05529134
- Testing
- PTW-002 10 mg/g gel
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Phoenicis Therapeutics
Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Simplex Kobner
Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
: Epidermolysis bullosa (EB) simplex is a rare orphan disease caused by a mutation in DNA leading to abnormal dominant keratins in the skin.
- Conditions
- Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Simplex Kobner, Weber-Cockayne Syndrome
- Trial name
- NCT03016715
- Testing
- Sirolimus 2%, Vehicle
- Where
- Australia
- Volunteers
- 8 people
- Sponsor
- Premier Specialists, Australia
Recessive Dystrophic Epidermolysis Bullosa
Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Recessive dystrophic epidermolysis bullosa (RDEB) is an incurable, devastating, inherited skin disease caused by mutations in the COL7A1 gene that encodes for type VII collagen (C7), the major component of anchoring fibrils…
- Trial name
- NCT03392909
- Testing
- Gentamicin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Southern California
Epidermolysis Bullosa Dystrophica
Growth Hormone in EB
Growth is extremely affected in epidermolysis bullosa patients
- Trial name
- NCT05390073
- Testing
- growth hormone level and insulin like growth factor 1
- Volunteers
- 50 people
- Sponsor
- Cairo University
Hereditary Epidermolysis Bullosa
Impact of Complex Care Training of Hereditary Epidermolysis Bullosa on Caregiver Burden (FIREB)
Hereditary epidermolysis bullosa (EBH) is a rare, orphan disease characterized by skin and mucous membrane fragility. The latest scientific data show that the proposed treatments are still in the experimental stage and that no…
- Trial name
- FIREB (NCT05248503)
- Testing
- Complex Care Training of Hereditary Epidermolysis Bullosa
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Epidermolysis Bullosa Simplex
Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex
The investigators hypothesize that palmar injections of botulinic toxin, via an inhibition of the sudation, would limit the occurrence of blisters in localized epidermolysis bullosa simplex (LEBS).
- Trial name
- EBTox (NCT03453632)
- Testing
- Botulinic toxin
- Where
- 4 sites in France
- Volunteers
- 18 people
- Sponsor
- University Hospital, Toulouse
Epidermolysis Bullosa Dystrophica
Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate)
Dystrophic epidermolysis bullosa hereditaria are genodermatosis responsible for formation of cutaneous bullous lesion arising spontaneously or after mechanical trauma.
- Trial name
- NCT00951964
- Where
- 5 sites in France
- Volunteers
- 18 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Epidermolysis Bullosa (EB)
An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa
The objective is to characterize the continued safety of SD-101 cream containing 6% allantoin in the treatment of the skin in patients with Simplex, Recessive Dystrophic, or JEB-nH EB.
- Trial name
- NCT07482813
- Testing
- SD-101 Dermal Cream (6%)
- Volunteers
- 80 people
- Sponsor
- Paradigm Therapeutics